H.C. Wainwright on Biogen (BIIB): 'Salanersen can help cement Biogen’s leadership in SMA'
Tweet Send to a Friend
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $187.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "Salanersen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
